1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc.

SUPN
Supernus Pharmaceuticals, Inc.US flagNASDAQ Global Market
43.29
USD
-0.10
- -
2.51BMarket Cap

Total Valuation

Supernus Pharmaceuticals, Inc. carries a market capitalization of 2.51B, placing it among publicly traded companies globally. Its enterprise value stands at 2.37B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.51B
Enterprise Value2.37B

Share Statistics

Supernus Pharmaceuticals, Inc. currently has 58.16M shares outstanding.

Shares Outstanding58.16M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 3.21, and the price-to-book ratio stands at 2.62.

PE RatioN/A
PS Ratio3.21
PB Ratio2.62
P/TBV Ratio6.12
P/FCF Ratio126.92
P/OCF Ratio134.09

Enterprise Valuation

On an enterprise value basis, Supernus Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 51.25 and an EV/FCF ratio of 102.76.

EV / Sales2.86
EV / EBITDA51.25
EV / EBITN/A
EV / FCF102.76

Financial Position

Supernus Pharmaceuticals, Inc. maintains a current ratio of 2.08, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.90, indicating elevated leverage, while an interest coverage ratio of 20.00 demonstrates strong ability to service its debt obligations.

Current Ratio2.08
Quick Ratio1.68
Debt / Equity3.90
Debt / EBITDA0.87
Interest Coverage20.00

Financial Efficiency

Return on Equity (ROE)-10.49
Return on Assets (ROA)-7.82
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.55

Taxes

Income Tax-13.58M
Effective Tax RateN/A

Stock Price Statistics

Supernus Pharmaceuticals, Inc.'s stock has declined approximately -8.08917% over the past 52 weeks. The 50-day moving average sits at 45.26, while the 200-day moving average is 48.31.

Beta (5Y)N/A
52-Week Price Change-8.08917%
50-Day Moving Average45.26
200-Day Moving Average48.31
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Supernus Pharmaceuticals, Inc. generated 830.44M in revenue and converted that into -109.89M in net income, yielding earnings per share of -1.91. EBITDA reached 46.31M, while operating income came in at -55.39M.

Revenue830.44M
Gross Profit731.41M
Operating Income-55.39M
Pretax Income-123.47M
Net Income-109.89M
EBITDA46.31M
EBIT-55.39M
Earnings Per Share (EPS)-1.91

Balance Sheet

Supernus Pharmaceuticals, Inc. holds 372.07M in cash and equivalents against 40.17M in total debt, resulting in a net debt position of -179.95M. Total book value stands at 1.03B, with working capital of 376.12M providing operational flexibility.

Cash & Cash Equivalents372.07M
Total Debt40.17M
Net Debt-179.95M
Equity (Book Value)1.03B
Book Value Per Share17.73
Working Capital376.12M

Cash Flow

Supernus Pharmaceuticals, Inc. produced 19.91M in operating cash flow over the past twelve months. After subtracting -1.12M in capital expenditures, free cash flow totaled 18.79M - equivalent to 0.33 per share.

Operating Cash Flow19.91M
Capital Expenditures-1.12M
Free Cash Flow18.79M
FCF Per Share0.33

Margins

Supernus Pharmaceuticals, Inc. operates with a gross margin of 88.07, reflecting its pricing power and cost economics. The operating margin of -6.67 and net profit margin of -13.23 provide insight into operational efficiency.

Gross Margin88.07
Operating Margin-6.67
Pretax Margin-14.87
Profit Margin-13.23
EBITDA Margin5.58

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-1.16
FCF Yield0.79

Scores

Supernus Pharmaceuticals, Inc. posts an Altman Z-Score of 6.16, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score6.16